- Home
- RLAY
as 07-04-2025 9:48am EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 576.1M | IPO Year: | 2020 |
| Target Price: | $18.40 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $10.72 | Next Earning Date: | 08-05-2025 |
| Revenue: | $7,679,000 | Revenue Growth: | -78.26% |
| Revenue Growth (this year): | 14.31% | Revenue Growth (next year): | -7.62% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bergstrom Donald A | RLAY | President, R&D | Apr 28 '25 | Sell | $3.09 | 31,562 | $95,381.30 | 610,962 | |
| Adams Brian | RLAY | Chief Legal Officer | Apr 28 '25 | Sell | $3.09 | 14,587 | $44,040.48 | 391,385 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Apr 28 '25 | Sell | $3.14 | 19,191 | $58,848.64 | 372,858 | |
| Rahmer Peter | RLAY | See remarks | Apr 28 '25 | Sell | $3.09 | 12,103 | $36,540.88 | 400,820 | |
| Patel Sanjiv | RLAY | President and CEO | Apr 23 '25 | Sell | $2.97 | 61,422 | $182,423.34 | 840,320 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
Insider Monkey
11 days ago
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
GlobeNewswire
24 days ago
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
Insider Monkey
a month ago
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
GlobeNewswire
a month ago
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
GlobeNewswire
a month ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Zacks
a month ago
What Makes Relay Therapeutics (RLAY) a New Buy Stock
Insider Monkey
2 months ago
Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now
GlobeNewswire
2 months ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.